$ARVN News

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

Arvinas (ARVN) Q2 2026 Earnings Call Transcript

Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14

Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11

Wedbush Maintains Neutral on Arvinas, Raises Price Target to $12

Arvinas Q2 Earnings Call Highlights

BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript